1
|
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024; 35:248-266. [PMID: 38307807 DOI: 10.1016/j.annonc.2023.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/17/2023] [Accepted: 11/28/2023] [Indexed: 02/04/2024] Open
Abstract
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
Collapse
|
2
|
Bolze P, Schoenen S, Margaillan M, Braga A, Sauthier P, Elias K, Seckl M, Winter M, Coulter J, Lok C, Joneborg U, Undurraga Malinverno M, Hajri T, Massardier J, You B, Golfier F, Goffin F. Chemotherapy is not needed when complete evacuation of gestational choriocarcinoma leads to hCG normalization. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2024; 50:108012. [PMID: 38350264 DOI: 10.1016/j.ejso.2024.108012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/23/2024] [Accepted: 02/07/2024] [Indexed: 02/15/2024]
Abstract
BACKGROUND The standard treatment for gestational choriocarcinoma is chemotherapy. OBJECTIVE To describe the risk of recurrence with expectant management of gestational choriocarcinoma that has reached a normal human chorionic gonadotropin level after tumor removal without adjuvant chemotherapy. METHODS A retrospective multicenter international cohort study was conducted from 1981 to 2017 involving 11 gestational trophoblastic disease reference centers with patient's follow-up extended until 2023. Clinical and biological data of included patients were extracted from each center's database. The inclusion criteria were i) histological diagnosis of gestational choriocarcinoma in any kind of placental tissue retrieved, ii) spontaneous normalization of human chorionic gonadotropin level following choriocarcinoma retrieval, iii) patient did not receive any oncological treatment for the choriocarcinoma, iv) and at least 6 months of follow-up after the first human chorionic gonadotropin level normalization. RESULTS Among 80 patients with retrieved gestational choriocarcinoma and whose human chorionic gonadotropin level normalized without any other oncological therapy, none had a recurrence of choriocarcinoma after a median follow-up of 50 months. The median interval between choriocarcinoma excision and human chorionic gonadotropin level normalization was 48 days. The International Federation of Gynecology and Obstetrics/World Health Organization risk score was ≤6 in 93.7% of the cases. CONCLUSIONS This multicenter international study reports that selected patients with gestational choriocarcinoma managed in gestational trophoblastic disease reference centers did not experience any relapse when the initial tumor evacuation is followed by human chorionic gonadotropin level normalization without any additional treatment. Expectant management may be a safe approach for highly selected patients.
Collapse
|
3
|
Monfort JB, Denamps J, Attencourt C, Lok C, Sevestre H, Chaby G. Early involvement of lymphatic vessels in pathophysiology of morphea. J Eur Acad Dermatol Venereol 2021; 36:e345-e346. [PMID: 34812536 DOI: 10.1111/jdv.17834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 11/04/2021] [Accepted: 11/17/2021] [Indexed: 11/29/2022]
|
4
|
Lof P, Van de Vrie R, Korse T, Van Gent M, Mom S, Rosier-van Dunné F, Van Baal M, Verhoeve H, Hermsen B, Verbruggen M, Hemelaar M, Van de Swaluw J, Knipscheer H, Huirne J, Westenberg S, Van der Noort V, Amant F, Van den Broek D, Lok C. 1069 Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with a pelvic mass to an oncology center? Diagnostics (Basel) 2021. [DOI: 10.1136/ijgc-2021-esgo.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
5
|
Say M, Tella E, Boccara O, Sauvage M, Bourrat E, Tian Y, Monfort JB, Lok C, Desierier F, Beneton N, Abasq-Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour JP, Plantin P, Sigal ML, Mazereeuw-Hautier J, Mahé E. Leg ulcers in childhood: A multicenter study in France. Ann Dermatol Venereol 2021; 149:51-55. [PMID: 34218940 DOI: 10.1016/j.annder.2021.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 03/30/2021] [Accepted: 05/19/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Leg ulcers in adults are a major public health concern. Their incidence increases with age and many causes have been identified, predominantly associated with vascular diseases. Leg ulcers in children and teenagers are less frequent. The aim of our study was to identify the causes of leg ulcers in children and teenagers, and to evaluate their management. METHODS This retrospective multicenter study was conducted by members of the Angio-dermatology Group of the French Society of Dermatology and of the French Society of Pediatric Dermatology. Data from children and teenagers (< 18 years), seen between 2008 and 2020 in 12 French hospitals for chronic leg ulcer (disease course>4 weeks), were included. RESULTS We included 27 patients, aged from 2.3 to 17.0 years. The most frequent causes of leg ulcer were: general diseases (n=9: pyoderma gangrenosum, dermatomyositis, interferonopathy, sickle cell disease, prolidase deficiency, scleroderma, Ehlers-Danlos syndrome), vasculopathies (n=8: hemangioma, capillary malformation, arteriovenous malformation), trauma (n=4: bedsores, pressure ulcers under plaster cast), infectious diseases (n=4: pyoderma, tuberculosis, Buruli ulcer) and neuropathies (n=2). Comorbidities (59.3%) and chronic treatments (18.5%) identified as risk factors for delayed healing were frequent. The average time to healing was 9.1 months. DISCUSSION Leg ulcers are less frequent in children and teenagers than in adults and their causes differ from those in adults. Comorbidities associated with delayed healing must be identified and managed. Children and teenagers tend to heal faster than adults, but a multidisciplinary management approach is necessary.
Collapse
|
6
|
Baltazard T, Senet P, Momar D, Picard C, Joachim C, Adas A, Lok C, Chaby G. Evaluation of timolol maleate gel for management of hard-to-heal chronic venous leg ulcers. Phase II randomised-controlled study. Ann Dermatol Venereol 2021; 148:228-232. [PMID: 33551214 DOI: 10.1016/j.annder.2020.11.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 08/27/2020] [Accepted: 11/05/2020] [Indexed: 01/15/2023]
Abstract
BACKGROUND Venous leg ulcers (VLUs) often take a very long time to heal. Timolol maleate has been reported as displaying efficacy in healing of VLUs. OBJECTIVES To evaluate the efficacy of timolol maleate gel in the management of hard-to-heal VLUs and to assess its safety as a topical agent during 12 weeks of use in combination with conventional treatment. METHODS A prospective, phase-II randomised-controlled trial with a sample size based on Fleming's one-stage design (P0=0.25, P1=0.45, alpha=0.1, beta=0.2) was planned. Patients with VLUs present for ≥24 weeks and with ≥50% granulation tissue were included. One drop of sustained-release timolol gel (Timoptol® LP 0.5%, Santen, Tampere, Finland) per 6 cm2 VLU area was applied every 2 days for 12 weeks in timolol-treated patients, as adjuvant therapy to the standard care protocol (interface dressing and multilayer venous compression). Controls received standard care alone. The primary endpoint was to obtain ≥40% reduction in ulcer area at week 12 (W12). RESULTS Forty-three patients were randomised to the study, with 40 receiving at least one treatment and included in the analysis: 21 timolol-treated patients and 19 controls (females: 70%; median age: 72.5 [range 35-93] years). At W12, ≥40% ulcer-area reduction was achieved in 14/21 (67%) timolol-treated patients vs. 6/19 (32%) controls. No serious adverse events occurred. Local wound infections not requiring systemic antibiotics occurred in 5 cases in the timolol group and in one case in the controls. CONCLUSIONS These results support the benefit and safety of using timolol maleate to manage hard-to-heal VLUs, but confirmation is required in a larger multicentre randomised phase-III study.
Collapse
|
7
|
Halle A, Tesson JR, Lok C, Attencourt C, Chaby G, Arnault JP. Caractéristiques microscopiques des engainements tumoraux péri-nerveux dans les carcinomes épidermoïdes cutanés : impact pronostique (76 patients). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Séméria L, Arnault JP, Dadban A, Cribier B, Poulet C, Attencourt C, Lok C, Chaby G. Porokératose linéaire avec transformation en carcinome épidermoïde de réponse favorable sous pembrolizumab et cisplatine. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Beauvillain Q, Dessirier F, Lombart F, Dadban A, Salle V, Morel P, Attencourt C, Lok C, Chaby G. Scléromyxœdème associé à une gammapathie monoclonale traité par lénalidomide et dexaméthasone. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Cohen-Sors R, Dubois C, Djeddi DD, Vanrenterghem A, Lombart F, Lok C, Chaby G, Dadban A. Manifestations dermatologiques chez les enfants traités par biothérapie. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Say M, Tella E, Boccara O, Mazereeuw Hautier J, Sauvage M, Bourrat E, Tian Y, Montfort J, Lok C, Dessierier F, Beneton N, Abasaq Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour J, Plantin P, Sigal M, Mahé E. Ulcères de membres inférieurs chez les enfants et les adolescents : étude multicentrique française. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli JF, Arnault JP, Adas A, Dairi M, Lok C, Chaby G. Severe erosive gingivostomatitis in a patient treated by vedolizumab. Dermatol Online J 2020. [DOI: 10.5070/d32610050468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
13
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli JF, Arnault JP, Adas A, Dairi M, Lok C, Chaby G. Severe erosive gingivostomatitis in a patient treated by vedolizumab. Dermatol Online J 2020; 26:13030/qt4w21m02k. [PMID: 33147674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 10/27/2020] [Indexed: 06/11/2023] Open
Abstract
Vedolizumab is a humanized monoclonal antibody that binds to the human a4β7 integrin and is approved for use in inflammatory bowel diseases. We describe a patient with severe, refractory erosive gingivostomatitis, which appeared a few days after the first dose of vedolizumab and resolved after discontinuation of the drug. We believe the gingivostomatitis to be a direct side effect of vedolizumab, rather than an extraintestinal manifestation of the underlying inflammatory bowel diseases. The clinicians need to be aware of this adverse event, which could be mistakenly considered as an extraintestinal manifestation of inflammatory bowel diseases.
Collapse
|
14
|
Dubois C, Brigant F, Lok C, Toulaimat H, Dillies AS, Zitouni N. Statut vaccinal antitétanique chez les patients en consultation de plaie et cicatrisation. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Martin H, Bursztejn A, Albuisson E, Leguern A, Mahe E, Villemur B, Blaise S, Perceau G, Goujon E, Lok C, Modiano P, Debure C, Guillot B, Maillard H, Say M, Carvalho-Lallement P, Dompmartin A, Journet-Tollhupp J, Schmutz JL, Senet P, Schoeffler A. Caractéristiques des plaies chroniques chez les toxicomanes : étude rétrospective de 58 patients. Ann Dermatol Venereol 2019; 146:793-800. [DOI: 10.1016/j.annder.2019.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Revised: 07/07/2019] [Accepted: 09/03/2019] [Indexed: 12/21/2022]
|
16
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli J, Lok C, Chaby G. Gingivostomatite érosive chez un patient traité par védolizumab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Adas A, Arnault JP, Attencourt C, Lok C, Chaby G. Secondary syphilis presenting as diffused folliculitis. J Eur Acad Dermatol Venereol 2019; 34:e191-e193. [PMID: 31774197 DOI: 10.1111/jdv.16109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Balthazard T, Lombart F, Hébert V, Chopinnaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. Single typical trichoscopic feature predictive of tinea capitis. Br J Dermatol 2019. [DOI: 10.1111/bjd.18495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Balthazard T, Lombart F, Hébert V, Chopinnaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. 单一典型的毛发镜检特征可预测头癣. Br J Dermatol 2019. [DOI: 10.1111/bjd.18507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Engbersen M, van’ t Sant I, Lok C, Lambregts D, Sonke G, Beets-Tan R, van Driel W, Lahaye M. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol 2019; 114:146-151. [DOI: 10.1016/j.ejrad.2019.03.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 03/07/2019] [Accepted: 03/12/2019] [Indexed: 11/15/2022]
|
21
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Baltazard T, Lombart F, Hébert V, Chopinaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. A single typical trichoscopic feature is predictive of tinea capitis: a prospective multicentre study. Br J Dermatol 2019; 181:1046-1051. [DOI: 10.1111/bjd.17866] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2019] [Indexed: 12/25/2022]
|
22
|
Dairi M, Dadban A, Arnault J, Lok C, Chaby G. Localized mycosis fungoides treated with laser‐assisted photodynamic therapy: a case series. Clin Exp Dermatol 2019; 44:930-932. [DOI: 10.1111/ced.13936] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2018] [Indexed: 12/01/2022]
|
23
|
Dubois C, Dadban A, Denamps J, Arnault JP, Lok C, Chaby G. Congenital melanocytic naevus and congenital strabismus. Clin Exp Dermatol 2019; 44:213-214. [DOI: 10.1111/ced.13622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2017] [Indexed: 11/27/2022]
|
24
|
Lombart F, Dillies A, Senet P, Pourchot D, Oro S, Modiano P, Barete S, Perceau G, Humbert P, Brault F, Poreaux C, Lorriaux A, Lok C, Chaby G. Calciphylaxie chez des patients non insuffisants rénaux : série de 10 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Philibert F, Arnault JP, Adjide C, Baltazard T, Dadban A, Chaby G, Lok C. Gestion d’une épidémie d’Acinetobacter baumanii résistant à l’imipénem (ABRI) dans un service de dermatologie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|